Exceptional Returns in AstraZeneca Call Options

Bullish option positions are delivering exceptional profits in AstraZeneca PLC (AZN).

On Nov. 7, Market Rebellion’s Unusual Activity Service identified significant bullish call buying, with 8,500 21November 90 calls bought for $0.22-$0.34 above the existing open interest of 2,511 contracts, with AZN shares trading at $84.92-$85.13.

Those 21November 90 calls traded as high as $1.07 today with the stock at $89.06, delivering impressive returns of approximately 282.14% from the initial entry price of $0.28. Meanwhile, AZN shares gained approximately 4.74% from their initial trading level around $85.03, demonstrating how options can deliver significantly amplified returns compared to simply owning the underlying stock.

This performance illustrates the power of options leverage when the directional thesis proves correct, though it’s important to note that this same leverage can work against traders when market moves go in the opposite direction.

Strong Q3 Earnings Beat Fuels Momentum

The primary catalyst driving AZN’s rally came just one day before the unusual call buying activity, with the company’s third quarter earnings report on November 6th, where the company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.14 by $0.05, with revenue of $15.19 billion compared to the consensus estimate of $14.75 billion. The earnings beat demonstrated AstraZeneca’s continued execution strength across its oncology and biopharmaceutical portfolios.

In the third quarter, AstraZeneca generated 10% year-on-year core revenue growth, 13% core operating profit growth, and 12% core EPS growth at constant currencies, with management reiterating its full-year guidance of high-single-digit revenue growth and low-double-digit core EPS growth. The maintained guidance reinforced investor confidence in the company’s ability to sustain momentum through year-end and beyond.

Oncology Portfolio Drives Revenue Beat

AstraZeneca reported total product sales of $14.365 billion for the third quarter of 2025, exceeding consensus estimates of $14.031 billion by approximately 2%, with the company’s oncology segment driving the revenue beat, including strong performances from key products like Enhertu, Truqap, Imfinzi/Imjudo, Tagrisso, Calquence, and Datroway. The diversified oncology portfolio demonstrated the company’s ability to drive growth across multiple franchises simultaneously.

AstraZeneca also confirmed it remains on track to achieve its mid-30s percentage core operating margin target for 2026 and its $80 billion revenue target for 2030, providing long-term visibility for investors. The ambitious 2030 revenue target of $80 billion represents nearly 50% growth from current levels, validating the strategic investments in oncology, rare diseases, and emerging therapeutic areas.

AZN was last trading at $89.05, up 1.79% intraday.